Were Analysts Bearish IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) This Week?

February 15, 2018 - By Richard Conner

 Were Analysts Bearish IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) This Week?

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Ratings Coverage

Among 2 analysts covering Intellipharmaceutics Intl (NASDAQ:IPCI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Intellipharmaceutics Intl had 6 analyst reports since December 31, 2015 according to SRatingsIntel. The stock of IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) earned “Buy” rating by Maxim Group on Friday, July 21. On Thursday, December 31 the stock rating was maintained by Maxim Group with “Buy”. H.C. Wainwright maintained it with “Buy” rating and $2.5 target in Monday, February 12 report. The stock of IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) earned “Buy” rating by Maxim Group on Tuesday, June 6. The firm has “Buy” rating by Maxim Group given on Friday, June 30. Below is a list of IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) latest ratings and price target changes.

12/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $2.5 Maintain
19/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $2.5 Initiates Coverage On

The stock decreased 0.67% or $0.005 during the last trading session, reaching $0.775. About 93,810 shares traded. IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) has risen 16.57% since February 15, 2017 and is uptrending. It has underperformed by 0.13% the S&P500.

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and makes novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. The company has market cap of $26.79 million. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. It currently has negative earnings. The companyÂ’s lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders.

More notable recent IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) news were published by: Globenewswire.com which released: “Intellipharmaceutics Announces Patent Litigation by Purdue against its Rexista …” on April 10, 2017, also Globenewswire.com with their article: “Intellipharmaceutics Receives Complete Response Letter from the FDA for …” published on September 25, 2017, Marketwatch.com published: “Intellipharmaceutics International Inc.” on July 27, 2017. More interesting news about IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) were released by: Globenewswire.com and their article: “Intellipharmaceutics Provides Operational Update” published on January 24, 2018 as well as Globenewswire.com‘s news article titled: “Intellipharmaceutics Reports on Launch of Additional Strengths of Generic …” with publication date: November 30, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.